The role of genetic analysis for predicting outcome of rheumatoid arthritis

References

• Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11:754–765. DOI:10.1016/j.autrev.2012.02.001. Epub 2012 Feb 23.
   PubMed Web of Science ®Google Scholar
• Cárdenas-Roldán J, Rojas-Villarraga A, Anaya J-M. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med. 2013;11:1.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New England J Med. 2003;349:1526–1533.
   PubMed Web of Science ®Google Scholar
• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2:119–125.
   PubMed Web of Science ®Google Scholar
• Scofield RH. Autoantibodies as predictors of disease. The Lancet. 2004;363:1544–1546.
   PubMed Web of Science ®Google Scholar
• Paola C-T, Oscar MP-F, Adriana R-V, et al. Shared HLA class II in six autoimmune diseases in Latin America: a meta-analysis. Autoimmun Diseas. 2012; 2012. Article ID 569728. DOI:10.1155/2012/569728
   Google Scholar
• Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol. 2008;22:583–604.
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006 Dec;36(3):182–188. Epub 2006 Oct 11.
   Google Scholar
• Rudan I, Sidhu S, Papana A, et al. Prevalence of rheumatoid arthritis in low–and middle–income countries: A systematic review and analysis. J Glob Health. 2015 Jun;5(1):010409. DOI:10.7189/jogh.05.010409.
   Google Scholar
• Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol. 2001;28:1718–1722.
   PubMed Web of Science ®Google Scholar
• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22:1–12.
   PubMed Web of Science ®Google Scholar
• Pollard L, Choy E, Scott D. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol. 2005;23:S43.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin. 2008;24:469–480.
   PubMed Web of Science ®Google Scholar
• Dayer J-M, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15–24. DOI:10.7189/jogh.05.010409.
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Landewé RB. Early aggressive therapy in rheumatoid arthritis: a ’window of opportunity’? Nat Clin Practice Rheumatol. 2005;1:2–3.
   PubMedGoogle Scholar
• Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46:894–898.
   PubMed Web of Science ®Google Scholar
• Cope AP. Studies of T-cell activation in chronic inflammation. Arthritis Res Ther. 2002;4:S197.
   Web of Science ®Google Scholar
• Edwards JC, Szczepański L, Szechiński J, et al. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. New England J Med. 2004;350:2572–2581.
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker JE, et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481–1488.
   PubMed Web of Science ®Google Scholar
• Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-α 1. Endocrinology. 2000;141:3956–3964.
   PubMed Web of Science ®Google Scholar
• Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282–290.
   PubMed Web of Science ®Google Scholar
• Tokuda H, Kanno Y, Ishisaki A, et al. Interleukin (IL)‐17 enhances tumor necrosis factor‐α‐stimulated IL‐6 synthesis via p38 mitogen‐activated protein kinase in osteoblasts. J Cell Biochem. 2004;91:1053–1061.
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345–1352.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Van Den Bersselaar L, Oppers-Walgreen B, et al. van den Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J Immunol. 2003;170:2655–2662.
   PubMed Web of Science ®Google Scholar
• Huber L, Distler O, Tarner I, et al. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. 2006;45:669–675.
   PubMed Web of Science ®Google Scholar
• Niederer F, Trenkmann M, Ospelt C, et al. Down‐regulation of microRNA‐34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis & Rheumatism. 2012;64:1771–1779.
   PubMed Web of Science ®Google Scholar
• Katchamart W, Johnson S, Lin HJL, et al. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res. 2010;62:1128–1143.
   PubMed Web of Science ®Google Scholar
• Van Der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease‐modifying antirheumatic drug–free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheumatol. 2009;60:2262–2271.
   PubMed Web of Science ®Google Scholar
• De Rooy DP, Van Der Linden MP, Knevel R, et al. Predicting arthritis outcomes—what can be learned from the Leiden Early Arthritis Clinic? Rheumatology. 2011;50:93–100.
   PubMed Web of Science ®Google Scholar
• Knevel R, Grondal G, Huizinga TW, et al. Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2012;71:707–709.
   PubMed Web of Science ®Google Scholar
• Silman A, MacGregor A, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Rheumatology. 1993;32:903–907.
   Web of Science ®Google Scholar
• Van Der Helm‐Van Mil A, Kern M, Gregersen PK, et al. Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis & Rheumatism. 2006;54:2028–2030.
   PubMed Web of Science ®Google Scholar
• Dörr S, Lechtenböhmer N, Rau R, et al. Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther. 2004;6:R199.
   PubMed Web of Science ®Google Scholar
• Knevel R, De Rooy D, Gregersen P, et al. Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts. Ann Rheum Dis. 2012;71:1753–1755.
   PubMed Web of Science ®Google Scholar
• Knevel R, Krabben A, Brouwer E, et al. van der Linden M. Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis. 2012;71:1651–1657.
   PubMed Web of Science ®Google Scholar
• Knevel R, Krabben A, Wilson A, et al. A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. Arthritis & Rheumatism. 2013;65:582–589.
   PubMed Web of Science ®Google Scholar
• Krabben A, Wilson A, Knevel R, et al. Genetic variants in theil-4andil-4receptor genes in association with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts. Arthritis & Rheumatism. 2012;64:S389.
   PubMed Web of Science ®Google Scholar
• Mewar D, Marinou I, Coote AL, et al. Association between radiographic severity of rheumatoid arthritis and shared epitope alleles: differing mechanisms of susceptibility and protection. Ann Rheum Dis. 2008;67:980–983.
   PubMed Web of Science ®Google Scholar
• Viatte S, Plant D, Han B, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. Jama. 2015;313:1645–1656.
   PubMed Web of Science ®Google Scholar
• Knevel R, Klein K, Somers K, et al. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis. 2014 Nov;73(11):2038–2046. DOI:10.7189/jogh.05.010409. Epub 2013 Aug 16.
   PubMed Web of Science ®Google Scholar
• Teare MD, Knevel R, Morgan MD, et al. Allele‐dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. Arthritis & Rheumatism. 2013;65:2555–2561.
   PubMed Web of Science ®Google Scholar
• Van Der Linden MP, Feitsma AL, Le Cessie S, et al. Association of a single‐nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis & Rheumatism. 2009;60:2242–2247.
   PubMed Web of Science ®Google Scholar
• Knevel R, De Rooy DP, Saxne T, et al. A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Res Ther. 2014;16:R108.
   PubMed Web of Science ®Google Scholar
• Danila MI, Westfall AO, Raman K, et al. van der Heijde DM. The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis. Genes Immun. 2015;16:446–451.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos A, Theodorou I, Boura P. TRAF1/C5 rs3761847 SNP is associated with severe pattern of rheumatoid arthritis in Greek patients. Open J Rheumatol Autoimmune Dis. 2016;6:10.
   Google Scholar
• Van Steenbergen HW, Rodríguez-Rodríguez L, Berglin E, et al. A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Res Ther. 2015;17:1.
   PubMed Web of Science ®Google Scholar
• Viatte S, Plant D, Lunt M, et al. Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage. J Rheumatol. 2013;40:144–156.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodriguez L, Ivorra-Cortes J, Carmona FD, et al. PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts. Arthritis Res Ther. 2015;17:306.
   PubMed Web of Science ®Google Scholar
• Marinou I, Healy J, Mewar D, et al. Association of interleukin‐6 and interleukin‐10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheumatol. 2007;56:2549–2556.
   PubMed Web of Science ®Google Scholar
• Constantin A, Lauwers‐Cancès V, Navaux F, et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA–DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis & Rheumatism. 2002;46:1754–1762.
   PubMed Web of Science ®Google Scholar
• Mattey D, Nixon N, Dawes P, et al. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun. 2004;5:147–149.
   PubMed Web of Science ®Google Scholar
• Buchs N, Di Giovine F, Silvestri T, et al. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun. 2001;2:222.
   PubMed Web of Science ®Google Scholar
• De Rooy DP, Tsonaka R, Andersson ML, et al. Genetic factors for the severity of ACPA-negative rheumatoid arthritis in 2 cohorts of early disease: a genome-wide study. J Rheumatol. 2015;42:1383–1391.
   PubMed Web of Science ®Google Scholar
• Torices S, Alvarez-Rodríguez L, Grande L, et al. A truncated variant of ASCC1, a novel inhibitor of NF-κB, is associated with disease severity in patients with rheumatoid arthritis. J Immunol. 2015;195:5415–5420.
   PubMed Web of Science ®Google Scholar
• Fontalba A, Martinez-Taboada V, Gutierrez O, et al. Deficiency of the NF-κB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J Immunol. 2007;179:4867–4873.
   PubMed Web of Science ®Google Scholar
• Knevel R, Rooy D, Zhernakova A, et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis & Rheumatism. 2013;65:1684–1693.
   PubMed Web of Science ®Google Scholar
• Scherer HU, Van Der Linden MM, Kurreeman FA, et al. Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2010 Mar;69(3):567–570. DOI:10.1136/ard.2008.106161.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ikari K, Yano K, et al. PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study. PLoS One. 2013;8:e61045.
   PubMed Web of Science ®Google Scholar
• Han SW, Sa KH, Kim SI, et al. FCRL3 gene polymorphisms contribute to the radiographic severity rather than susceptibility of rheumatoid arthritis. Hum Immunol. 2012;73:537–542.
   PubMed Web of Science ®Google Scholar
• Nam EJ, Kim KH, Han SW, et al. The− 283C/T polymorphism of the DNMT3B gene influences the progression of joint destruction in rheumatoid arthritis. Rheumatol Int. 2010;30:1299–1303.
   PubMed Web of Science ®Google Scholar
• Zapico I, Coto E, Rodriguez A, et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 2000;1:288.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Carreón AA, Zúñiga J, Hernández-Pacheco G, et al. Tumor necrosis factor-alpha− 308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans. J Autoimmun. 2005;24:63–68.
   PubMed Web of Science ®Google Scholar
• Baugh J, Chitnis S, Donnelly S, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3:170–176.
   PubMed Web of Science ®Google Scholar
• Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42: 508–514. Epub 2010/05/11.
   PubMed Web of Science ®Google Scholar
• Teare MD, Knevel R, Morgan MD, et al. Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. Arthritis Rheum. 2013;65:2555–2561.
   PubMed Web of Science ®Google Scholar
• Muthana M, Hawtree S, Wilshaw A, et al. C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proc Natl Acad Sci. 2015;112:11618–11623.
   PubMed Web of Science ®Google Scholar
• Wollheim FA. Markers of disease in rheumatoid arthritis. Curr Opin Rheumatol. 2000;12:200–204.
   PubMed Web of Science ®Google Scholar